Rare Disease Diagnostics Market Report 2026

The rare disease diagnostics market size has grown strongly in recent years. It will grow from $38.14 billion in 2025 to $41.91 billion in 2026 at a compound annual growth rate (CAGR) of 9.9%. The growth in the historic period can be attributed to expansion of genetic testing availability, rising awareness of rare diseases among clinicians, increasing use of molecular diagnostics, growth of specialized diagnostic laboratories, improved access to advanced imaging technologies.

The rare disease diagnostics market size is expected to see rapid growth in the next few years. It will grow to $62.18 billion in 2030 at a compound annual growth rate (CAGR) of 10.4%. The growth in the forecast period can be attributed to expansion of personalized medicine adoption, rising investments in genomics research, growing demand for early-stage rare disease detection, increasing integration of ai-driven diagnostic tools, expansion of rare disease screening programs. Major trends in the forecast period include increasing adoption of next-generation sequencing diagnostics, rising use of multi-gene panel testing, growing integration of advanced imaging in rare disease diagnosis, expansion of centralized rare disease testing centers, enhanced focus on early and accurate diagnosis.

The rising incidence of rare diseases is expected to drive the growth of the rare disease diagnostics market in the coming years. Rare diseases are medical conditions that affect a relatively small segment of the population compared to more common illnesses and often require specialized diagnostic tools for timely and accurate identification. Rare disease diagnostics support improved disease management, assist in identifying potential therapeutic options, and help minimize unnecessary or potentially harmful treatments, thereby enabling more effective patient care. For instance, in March 2025, according to Kidney Research UK, a UK-based kidney disease charity, the rare kidney disease landscape currently includes more than 150 distinct conditions, affecting an estimated 70 per 100,000 people, with most cases arising from genetic alterations. Therefore, the increasing incidence of rare diseases is driving the growth of the rare disease diagnostics market.

Major companies operating in the rare disease diagnostics market are concentrating on the development of advanced technologies, such as high-sensitivity whole genome sequencing platforms, to enhance diagnostic accuracy, broaden variant detection, and speed up the identification of complex rare disorders. High-sensitivity whole genome sequencing platforms allow comprehensive analysis of nearly all disease-causing genetic variants in a single test, supporting earlier and more precise diagnoses. For instance, in April 2023, Centogene GmbH, a Germany-based rare disease company, introduced CentoGenome, an advanced next-generation sequencing based whole genome sequencing solution designed for diagnosing rare and neurodegenerative diseases. The platform provides extensive variant coverage, including copy number variations linked to spinal muscular atrophy and complex pathogenic variants associated with Gaucher disease and GBA1-related Parkinson’s disease. In addition, CentoGenome incorporates PCR-free technology to minimize sequencing bias in challenging genomic regions, delivering higher-quality data and deeper insights into coding, regulatory, and intronic regions to support accurate clinical interpretation.

In August 2024, Labcorp, a US-based diagnostics and laboratory services company, acquired selected assets from Invitae for an undisclosed amount. Through this acquisition, Labcorp aims to strengthen its presence in the rare disease diagnostics market by integrating Invitae’s advanced genetic testing capabilities and expanding access to high-complexity genomic diagnostics for underserved patient populations. Invitae is a US-based genetic testing and diagnostics company focused on rare disease testing.

Major companies operating in the rare disease diagnostics market are Thermo Fisher Scientific Inc., Roche Diagnostics, Laboratory Corporation of America Holdings, Quest Diagnostics Incorporated, Eurofins Scientific SE, Agilent Technologies Inc., PerkinElmer Inc., Sanofi Genzyme, Illumina Inc., Bio Rad Laboratories Inc., Qiagen NV, OPKO Health Inc., Natera Inc., Invitae Corporation, BGI Genomics Co. Ltd., 23andMe Holding Co., Ambry Genetics Corporation, Centogene N.V., GENEWIZ Inc., Blueprint Genetics Inc., Oxford Gene Technology Limited, Strand Life Sciences Pvt. Ltd., RareCyte Inc., Sophia Genetics SA, Foundation Medicine Inc.

North America was the largest region in the rare disease diagnostics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the rare disease diagnostics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the rare disease diagnostics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the rare disease diagnostics market by increasing the cost of imported sequencing instruments, imaging equipment, reagents, diagnostic kits, and laboratory consumables used in genetic and imaging-based tests. Diagnostic laboratories and hospital systems in North America and Europe are most affected due to reliance on imported high-end diagnostic technologies, while Asia-Pacific faces cost pressure on reagent and equipment imports. These tariffs are increasing operational costs and extending procurement timelines. However, they are also encouraging domestic manufacturing of diagnostic kits, local reagent production, and regional expansion of testing capabilities, supporting long-term supply chain resilience.

The rare disease diagnostics market research report is one of a series of new reports that provides rare disease diagnostics market statistics, including rare disease diagnostics industry global market size, regional shares, competitors with a rare disease diagnostics market share, detailed rare disease diagnostics market segments, market trends and opportunities, and any further data you may need to thrive in the rare disease diagnostics industry. This rare disease diagnostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Rare disease diagnostics refers to the methods and processes used to identify and diagnose medical conditions that are classified as rare or uncommon. These diagnostic approaches support early detection and accurate diagnosis, as well as the selection of targeted and personalized treatment strategies for rare disorders.

The primary tests involved in rare disease diagnostics include genetic tests, general laboratory tests, and imaging tests. A genetic test is a laboratory procedure that analyzes chromosomes, genes, or gene expression in human cells or tissues. Various technologies are used, including capillary sequencing, whole genome sequencing, whole exome sequencing, and microarrays, which utilize different sample types such as DNA samples, buccal swabs, blood, and saliva. These tests are applied across multiple disease areas, including gastroenterological diseases, endocrine and metabolic disorders, hematology and oncology conditions, dermatological diseases, cardiovascular disorders, and neurological diseases. These diagnostic services are used by a range of end users, including hospital laboratories, diagnostic laboratories, genetic testing laboratories, and cancer research laboratories.

The rare disease diagnostics market consists of revenues earned by entities by providing services such as clinical evaluation, parallel sequencing, targeted sequencing, laboratory testing, and specialist consultation. The market value includes the value of related goods sold by the service provider or included within the service offering. The rare disease diagnostics market also includes sales of vision evaluation instruments, blood pressure cuffs, cardiac monitors, and advanced imaging equipment. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.